SCHEMBL30910050

SCHEMBL30910050

CC(C(=O)N1CCN(c2ccccc2)c2ccccc21)N1CCCCC1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ GAA P10253 3/20 0.46
▸ ALDH1A1 P00352 5/20 0.45
▸ KDM4E B2RXH2 3/20 0.45
▸ LMNA P02545 3/20 0.45
▸ MAPT P10636 2/20 0.45
▸ TSHR P16473 1/20 0.45
▸ MEN1 O00255 2/20 0.43
▸ KMT2A Q03164 2/20 0.43
▸ TDP1 Q9NUW8 1/20 0.42
▸ ATM Q13315 1/20 0.42
▸ SMN1; SMN2 Q16637 3/20 0.41
▸ NPSR1 Q6W5P4 1/20 0.41
▸ DRD4 P21917 1/20 0.41
▸ SIGMAR1 Q99720 2/20 0.40
▸ MAOB P27338 1/20 0.40
▸ CHRNA1 P02708 1/20 0.39
▸ CHRNG P07510 1/20 0.39
▸ CHRNB1 P11230 1/20 0.39
▸ CHRNB2 P17787 1/20 0.39
▸ SLC6A2 P23975 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL26088160 1.00 GAA (0.46) GAAALDH1A1KDM4ELMNAMAPT
SCHEMBL26092208 0.99 GAA (0.47) GAAALDH1A1KDM4ELMNAMAPT
SCHEMBL30379742 0.99 GAA (0.47) GAAALDH1A1KDM4ELMNAMAPT
SCHEMBL30379078 0.90 DRD4 (0.50) GAAALDH1A1KDM4ELMNAMAPT
SCHEMBL26092095 0.90 DRD4 (0.50) GAAALDH1A1KDM4ELMNAMAPT
SCHEMBL30378556 0.90 CHRNB2 (0.43) GAAALDH1A1KDM4ELMNAMAPT
SCHEMBL26090563 0.90 CHRNB2 (0.43) GAAALDH1A1KDM4ELMNAMAPT
SCHEMBL30910085 0.89 DRD4 (0.51) GAAALDH1A1KDM4ELMNAMAPT
SCHEMBL30379034 0.89 GAA (0.43) GAAALDH1A1KDM4ELMNAMAPT
SCHEMBL26092223 0.89 DRD4 (0.51) GAAALDH1A1KDM4ELMNAMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250002464-A1 NOVEL COMPOUND AND PHARMACEUTICAL COMPOSITION COMPRISING SAME SAPIENSBIO INC. (KR) 2025-01-02 — — US claimed
EP-4421070-A1 NOVEL COMPOUND AND PHARMACEUTICAL COMPOSITION COMPRISING SAME Sapiensbio Inc. (KR) 2024-08-28 — — EP claimed
CN-118119612-A Novel compounds and pharmaceutical compositions comprising the same 萨皮恩斯生物有限公司 2024-05-31 — — CN claimed
US-20250002464-A1 NOVEL COMPOUND AND PHARMACEUTICAL COMPOSITION COMPRISING SAME SAPIENSBIO INC. (KR) 2025-01-02 — — US disclosed
EP-4421070-A1 NOVEL COMPOUND AND PHARMACEUTICAL COMPOSITION COMPRISING SAME Sapiensbio Inc. (KR) 2024-08-28 — — EP disclosed
CN-118119612-A Novel compounds and pharmaceutical compositions comprising the same 萨皮恩斯生物有限公司 2024-05-31 — — CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250002464-A1 NOVEL COMPOUND AND PHARMACEUTICAL COMPOSITION COMPRISING SAME RHOA, ACTR2, MFAP1 GAA 1343/4885ALDH1A1 2159/4885KDM4E 1932/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback